A major discovery by Australian researchers of a key driver of prostate cancer could lead to the next generation of targeted ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

ZERO Prostate Cancer (ZERO), the nation's leading advocacy and support foundation for prostate cancer awareness, has announced the launch of Blitz the Barriers during Cancer Prevention Month. This ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Providence Alaska Medical Center will be the first in the state to offer Pluvicto, an innovative therapy for metastatic ...

The oncology sector is experiencing an unprecedented wave of innovation in 2025, with rising cancer rates fueling the demand for better detection, treatment, and investment in life-saving technologies ...

Kairos Pharma (NYSE American: KAPA) announced that Cedars-Sinai Medical Center, through its academic partnership with the company, has received $600 ...

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial co ...

In a major development, Union Minister Prataprao Jadhav announced that cancer vaccines for women will be available soon.

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity ...

Ahmedabad: Zydus Lifesciences Ltd., a global healthcare company has announced that its wholly owned subsidiary, Zydus ...